Aspirin/AIDS study
This article was originally published in The Tan Sheet
Executive Summary
Community Research Initiative on AIDS plans to conduct a study to examine whether aspirin plays a role in inhibiting HIV. The trial is expected to include 46 randomized, blinded, HIV- positive, asymptomatic people who will take either 1 g aspirin four times daily or acetaminophen as a control. The eight-week study will begin enrolling participants in August. CRIA is negotiating to obtain drug donations and funding for the study. CRIA estimates the cost of the study at about $ 80,000
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning